Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/95084
DC FieldValueLanguage
dc.contributor.authorVeloso, Caroline D.-
dc.contributor.authorBelew, Getachew D.-
dc.contributor.authorFerreira, Luciana L.-
dc.contributor.authorGrilo, Luís F.-
dc.contributor.authorJones, John Griffith-
dc.contributor.authorPortincasa, Piero-
dc.contributor.authorSardão, Vilma A.-
dc.contributor.authorOliveira, Paulo J.-
dc.date.accessioned2021-06-21T12:12:44Z-
dc.date.available2021-06-21T12:12:44Z-
dc.date.issued2019-
dc.identifier.issn13816128pt
dc.identifier.urihttps://hdl.handle.net/10316/95084-
dc.description.abstractCardiovascular diseases (CVDs) are a leading risk factor for mortality worldwide and the number of CVDs victims is predicted to rise through 2030. While several external parameters (genetic, behavioral, environmental and physiological) contribute to cardiovascular morbidity and mortality; intrinsic metabolic and functional determinants such as insulin resistance, hyperglycemia, inflammation, high blood pressure and dyslipidemia are considered to be dominant factors.pt
dc.language.isoengpt
dc.relationPTDC/DTP-FTO/2433/2014pt
dc.relationPOCI-01-0145-FEDER-016659pt
dc.relationPOCI-01-0145-FEDER-007440pt
dc.relationMarie Skłodowska-Curie Grant Agreement No. 722619 (FOIE GRAS)pt
dc.rightsembargoedAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectCardiovascular diseases; Mitochondria; cardiovascular risk; insulin resistance; metabolism; mitochondrial dysfunction.pt
dc.subject.meshAnimalspt
dc.subject.meshCardiovascular Diseasespt
dc.subject.meshDyslipidemiaspt
dc.subject.meshHumanspt
dc.subject.meshHyperglycemiapt
dc.subject.meshHypertensionpt
dc.subject.meshInflammationpt
dc.subject.meshInsulin Resistancept
dc.subject.meshMitochondriapt
dc.subject.meshOxidative Stresspt
dc.subject.meshRatspt
dc.subject.meshReactive Oxygen Speciespt
dc.subject.meshRisk Factorspt
dc.titleA Mitochondrial Approach to Cardiovascular Risk and Diseasept
dc.typearticle-
degois.publication.firstPage3175-3194pt
degois.publication.lastPage3194pt
degois.publication.issue29pt
degois.publication.titleCurrent Pharmaceutical Designpt
dc.relation.publisherversionhttps://www.eurekaselect.com/174592/articlept
dc.peerreviewedyespt
dc.identifier.doi10.2174/1389203720666190830163735pt
degois.publication.volume25pt
dc.date.embargo2019-06-30*
uc.date.periodoEmbargo180pt
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.openairetypearticle-
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.cerifentitytypePublications-
crisitem.project.grantnoinfo:eu-repo/grantAgreement/EC/H2020/722619/EU/Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Fatty Liver Disease-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.orcid0000-0002-3745-3885-
crisitem.author.orcid0000-0001-7014-4614-
crisitem.author.orcid0000-0002-5201-9948-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
2019.07.22_Final paper Veloso et al.pdf962.85 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

18
checked on Nov 27, 2023

WEB OF SCIENCETM
Citations

16
checked on Nov 2, 2023

Page view(s)

142
checked on Aug 28, 2024

Download(s)

773
checked on Aug 28, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons